AppointmentsConservative MP Dr Dan Poulter Joins UK Cannabis Company’s...

Conservative MP Dr Dan Poulter Joins UK Cannabis Company’s Board Of Directors


MEDICAL cannabis company Kanabo Group has appointed Dr Dan Poulter MP as a Non-Executive Director to the board.

Dr Poulter, a former UK Government health minister, and chairperson of the All-Party Parliamentary Group for Global Health, has in-depth knowledge of the drugs and medicines regulatory framework in the UK. 

A practicing NHS Psychiatrist, he believes that prescribed cannabis products could bring considerable health benefits to help people experiencing mental ill health and distress. 

Dr Poulter

Dr Poulter said: “As a doctor, I am increasingly aware of the potential of cannabis-based medicines. Cannabis products are fast becoming available that could deliver significant improvements to the lives of thousands of patients suffering from conditions ranging from chronic pain to post traumatic stress disorder.”

Avihu Tamir, CEO, Kanabo Group, said: “We are delighted to welcome Dr Dan Poulter, MP as a Non-Executive Director to our board. Dan brings a wealth of knowledge and insight into the business that strengthens our team as we build a medicinal cannabis market in the UK and Europe.” 

 Chairman of the Board, David Tsur, added: “We are delighted that Dr Dan Poulter has joined us and we’d like to warmly welcome him. He brings a wealth of experience and I’m sure will be a very valuable addition to the board. It’s an exciting period for Kanabo to execute the company’s business plan and to expand its activity and strategic partnerships.”

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

Germany Seeing Sense, High Tide Strikes Deal With Major German Player, European Expansion For Bedrocan, Danish Buy-Out, Greek First, £2m UK Hemp Boost

THE German Government’s refreshingly honest approach to drugs and addiction is being demonstrated with a focus on the harms...

European Cannabis Stocks Review: Akanda Announces ‘First Significant Revenue Above Initial Projections’, Jazz Pharma Reimbursement Recommendation & Kanabo Climbs

Akanda  Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not...

15% Of European Consumers Have Tried CBD, But Industry Held Back By ‘High Turnover Rate’ Of Users

THE European CBD market is set to see a ‘massive influx’ of previous and new consumers to the market...

Malta’s Pioneering Legal Cannabis Club Framework Announced, But Concerns Raised Licence Fees Could Push Many To Black Market

ON Friday (January 27) the Maltese Authority for the Responsible Use of Cannabis (ARUC) announced new guidelines set to...

Cannovum AG Establishes Cultivation Alliance For Germany

PRESS RELEASE CANNOVUM AG is currently founding the premier cultivation alliance for recreational cannabis in Germany. The aim of the...

Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England

PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals ("GW"; now...

Must read

You might also likeRELATED
Recommended to you